Feb 28 (Reuters) - Cytokinetics Inc said on
Tuesday the U.S health regulator declined to approve its oral
drug for a type of heart failure, citing lack of sufficient data
to show the drug was effective.The U.S. Food and Drug Administration's decision comes after
a panel of outside experts in December recommended against
allowing the use of the drug due to safety concerns.
(Reporting by Pratik Jain and Bhanvi Satija in Bengaluru;
Editing by Shinjini Ganguli)